Posted by Michael Wonder on 14 May 2020
ICER’s cost model is not only wrong it’s also dangerous
11 May 2020 - There they go again.
In the midst of the race for an effective COVID-19 treatment, ICER has performed an incomplete analysis of remdesivir in order to produce a cost estimate that is, by definition, precisely wrong.
Remdesivir, produced by Gilead, is an experimental anti-viral medication that did not work as hoped to treat hepatitis C, but is showing promise as a treatment for viruses such as SARS and COVID-19.
